Recall Enforment Report D-383-2014

Recall Details

Drug Recall Enforcement Report Class II voluntary initiated by Sandoz Incorporated, originally initiated on 10-22-2013 for the product Tacrolimus Capsules, USP, 0.5 mg, 100 capsules/bottle, Rx only, Manufactured in India by Sandoz Private ltd. for Sandoz Inc., Princeton, NJ NDC 0781-2102-01 The product was recalled due to cross contamination with other products: findings of carryover of trace amounts of a previously manufactured product fluvastatin. The product was distributed nationwide and the recall is currently terminated.

Field Name Field Value
Event ID 66531 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number D-383-2014 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern Nationwide What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description Tacrolimus Capsules, USP, 0.5 mg, 100 capsules/bottle, Rx only, Manufactured in India by Sandoz Private ltd. for Sandoz Inc., Princeton, NJ NDC 0781-2102-01
Reason For Recall Cross Contamination with Other Products: findings of carryover of trace amounts of a previously manufactured product fluvastatin What is the Reason for Recall?
Information describing how the product is defective.
Product Quantity 12,521 bottles Product Quantity
The amount of product subject to recall.
Voluntary Mandated Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date 01-01-2014
Recall Initiation Date 10-22-2013 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.
Termination Date 07-10-2014 What is the Date Terminated?
The date that FDA terminated the recall.
Initial Firm Notification Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type Drugs
Recalling Firm Sandoz Incorporated
Code Info Lots DE9898, DE9900, DE9903, DE9908, DE9911. Exp. 06/14 Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages 0781-2102-01; 0781-2103-01; 0781-2104-01
Status Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.

Recalled Products

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
0781-2102Tacrolimus TacrolimusCapsuleOralSandoz IncHuman Prescription Drug
0781-2103Tacrolimus TacrolimusCapsuleOralSandoz IncHuman Prescription Drug
0781-2104Tacrolimus TacrolimusCapsuleOralSandoz IncHuman Prescription Drug